New Delhi: CSIR in collaboration with Laxai Life Sciences Pvt. Ltd., has initiated Phase-II clinical trial with anti-helminitic drug Niclosamide for treatment of Covid-19. The trial is a multi-centric, phase-II, randomized, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients. Niclosamide has been extensively used […]
CSIR India and Laxai Life Sciences initiate clinical trials of promising repurposed drug Niclosamide for treatment of Covid-19
- Post author:admin
- Post published:June 6, 2021
- Post category:Uncategorized